Comparison of Immunity Generated by Nucleic Acid-, MF59-, and ISCOM-Formulated Human Immunodeficiency Virus Type 1 Vaccines in Rhesus Macaques: Evidence for Viral Clearance

ABSTRACT The kinetics of T-helper immune responses generated in 16 mature outbred rhesus monkeys (Macaca mulatta) within a 10-month period by three different human immunodeficiency virus type 1 (HIV-1) vaccine strategies were compared. Immune responses to monomeric recombinant gp120SF2 (rgp120) when the protein was expressed in vivo by DNA immunization or when it was delivered as a subunit protein vaccine formulated either with the MF59 adjuvant or by incorporation into immune-stimulating complexes (ISCOMs) were compared. Virus-neutralizing antibodies (NA) against HIV-1SF2 reached similar titers in the two rgp120SF2 protein-immunized groups, but the responses showed different kinetics, while NA were delayed and their levels were low in the DNA-immunized animals. Antigen-specific gamma interferon (IFN-γ) T-helper (type 1-like) responses were detected in the DNA-immunized group, but only after the fourth immunization, and the rgp120/MF59 group generated both IFN-γ and interleukin-4 (IL-4) (type 2-like) responses that appeared after the third immunization. In contrast, rgp120/ISCOM-immunized animals rapidly developed marked IL-2, IFN-γ (type 1-like), and IL-4 responses that peaked after the second immunization. To determine which type of immune responses correlated with protection from infection, all animals were challenged intravenously with 50 50% infective doses of a rhesus cell-propagated, in vivo-titrated stock of a chimeric simian immunodeficiency virus-HIVSF13 construct. Protection was observed in the two groups receiving the rgp120 subunit vaccines. Half of the animals in the ISCOM group were completely protected from infection. In other subunit vaccinees there was evidence by multiple assays that virus detected at 2 weeks postchallenge was effectively cleared. Early induction of potent type 1- as well as type 2-like T-helper responses induced the most-effective immunity.

[1]  K. Überla,et al.  A Pathogenic Threshold of Virus Load Defined in Simian Immunodeficiency Virus- or Simian-Human Immunodeficiency Virus-Infected Macaques , 1998, Journal of Virology.

[2]  G. Ott,et al.  A comparison of biodegradable microparticles and MF59 as systemic adjuvants for recombinant gD from HSV-2. , 1998, Vaccine.

[3]  Dennis R. Burton,et al.  Why do we not have an HIV vaccine and how can we make one? , 1998, Nature Medicine.

[4]  D. Baltimore,et al.  HIV Vaccines—where are we going? , 1998, Nature Medicine.

[5]  J. Heeney,et al.  The role of type‐1 and type‐2 T‐helper immune responses in HIV‐1 vaccine protection , 1998, Journal of medical primatology.

[6]  J. Heeney,et al.  A clinically relevant HIV‐1 subunit vaccine protects rhesus macaques from in vivo passaged simian–human immunodeficiency virus infection , 1998, AIDS.

[7]  T. Lehner,et al.  Targeted lymph‐node immunization with whole inactivated simian immunodeficiency virus (SIV) or envelope and core subunit antigen vaccines does not reliably protect rhesus macaques from vaginal challenge with SIVmac251 , 1998, AIDS.

[8]  E. Rosenberg,et al.  Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. , 1997, Science.

[9]  M. McElrath,et al.  Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. , 1997, The New England journal of medicine.

[10]  C. Cheng‐Mayer,et al.  Comparison of in vitro and in vivo infectivity of different clade B HIV-1 envelope chimeric simian/human immunodeficiency viruses in Macaca mulatta. , 1997, Virology.

[11]  M. Villacrés-Eriksson,et al.  In vivo and in vitro induction of IL-6 by Quillaja saponaria molina triterpenoid formulations. , 1997, Cytokine.

[12]  D. Montefiori,et al.  Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[13]  J. Clements,et al.  Gene gun‐based nucleic acid immunization alone or in combination with recombinant vaccinia vectors suppresses virus burden in rhesus macaques challenged with a heterologous SIV , 1997, Immunology and cell biology.

[14]  J. Haynes,et al.  Manipulation of HIV-1 gp120-specific immune responses elicited via gene gun-based DNA immunization. , 1997, Vaccine.

[15]  H. Robinson,et al.  Nucleic acid vaccines: an overview. , 1997, Vaccine.

[16]  K. Steimer,et al.  Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit. , 1997, Vaccine.

[17]  K. Steimer,et al.  Enhancement of immunodeficiency virus-specific immune responses in DNA-immunized rhesus macaques. , 1997, Vaccine.

[18]  A. Prince,et al.  Successful nucleic acid based immunization of newborn chimpanzees against hepatitis B virus. , 1997, Vaccine.

[19]  D. Weiner,et al.  Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination , 1997, Nature Medicine.

[20]  N. Letvin,et al.  HIV-1 env DNA vaccine administered to rhesus monkeys elicits MHC class II-restricted CD4+ T helper cells that secrete IFN-gamma and TNF-alpha. , 1997, Journal of immunology.

[21]  A. Sjölander,et al.  Iscoms containing purified Quillaja saponins upregulate both Th1-like and Th2-like immune responses. , 1997, Cellular immunology.

[22]  R. Webster,et al.  Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization. , 1997, Journal of immunology.

[23]  G. Trinchieri,et al.  Immunomodulation by Quillaja saponaria adjuvant formulations: in vivo stimulation of interleukin 12 and its effects on the antibody response. , 1997, Cytokine.

[24]  G. Nest,et al.  MF59 adjuvant enhances the antibody response to recombinant hepatitis B surface antigen vaccine in primates. , 1996, The Journal of infectious diseases.

[25]  R. D. Keys,et al.  Immunization with DNA vaccines encoding glycoprotein D or glycoprotein B, alone or in combination, induces protective immunity in animal models of herpes simplex virus-2 disease. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[26]  H. Greenberg,et al.  Protection against rotavirus infections by DNA vaccination. , 1996, The Journal of infectious diseases.

[27]  J. Haynes,et al.  Influenza virus nucleoprotein-specific immunoglobulin G subclass and cytokine responses elicited by DNA vaccination are dependent on the route of vector DNA delivery , 1996, Journal of virology.

[28]  C. Walker,et al.  Induction of cytotoxic T lymphocytes by intramuscular immunization with plasmid DNA is facilitated by bone marrow-derived cells. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[29]  J. Sodroski,et al.  Utility of SHIV for testing HIV-1 vaccine candidates in macaques. , 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[30]  D. Weiner,et al.  In vivo protective anti‐HIV immune responses in non‐human primates through DNA immunization , 1996, Journal of medical primatology.

[31]  E. Raz,et al.  Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[32]  J. Mullins,et al.  Simian immunodeficiency virus-specific cytotoxic T-lymphocyte induction through DNA vaccination of rhesus monkeys , 1996, Journal of virology.

[33]  J. Heeney,et al.  Enumeration of lymphokine‐secreting cells as a quantitative measure for cellular immune responses in rhesus macaques , 1995, Journal of medical primatology.

[34]  J. Heeney,et al.  Protection from HIV-1 envelope-bearing chimeric simian immunodeficiency virus (SHIV) in rhesus macaques infected with attenuated SIV: consequences of challenge. , 1995, AIDS.

[35]  J. Mullins,et al.  Simian Immunodeficiency Virus DNA Vaccine Trial in Macaques , 1995, Journal of virology.

[36]  E. Ido,et al.  Construction of human immunodeficiency virus 1/simian immunodeficiency virus strain mac chimeric viruses having vpr and/or nef of different parental origins and their in vitro and in vivo replication. , 1995, The Journal of general virology.

[37]  V. Srikantan,et al.  Induction of humoral and cellular immune responses to the human immunodeficiency type 1 virus in nonhuman primates by in vivo DNA inoculation. , 1995, Virology.

[38]  C. Cheng‐Mayer,et al.  Persistent infection of rhesus macaques with T-cell-line-tropic and macrophage-tropic clones of simian/human immunodeficiency viruses (SHIV). , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[39]  G. Nest,et al.  Systemic cytokine profiles in BALB/c mice immunized with trivalent influenza vaccine containing MF59 oil emulsion and other advanced adjuvants. , 1994, Journal of immunology.

[40]  D. Fuller,et al.  A qualitative progression in HIV type 1 glycoprotein 120-specific cytotoxic cellular and humoral immune responses in mice receiving a DNA-based glycoprotein 120 vaccine. , 1994, AIDS research and human retroviruses.

[41]  A. Osterhaus,et al.  Major histocompatibility complex class I-associated vaccine protection from simian immunodeficiency virus-infected peripheral blood cells , 1994, The Journal of experimental medicine.

[42]  F. Chiodi,et al.  Long-standing protection of macaques against cell-free HIV-2 with a HIV-2 iscom vaccine. , 1994, Journal of acquired immune deficiency syndromes.

[43]  J. Ulmer,et al.  Heterologous protection against influenza by injection of DNA encoding a viral protein. , 1993, Science.

[44]  K. Steimer,et al.  Native but not denatured recombinant human immunodeficiency virus type 1 gp120 generates broad-spectrum neutralizing antibodies in baboons , 1992, Journal of virology.

[45]  C. Cheng‐Mayer,et al.  Host range, replicative, and cytopathic properties of human immunodeficiency virus type 1 are determined by very few amino acid changes in tat and gp120 , 1991, Journal of virology.

[46]  K. Steimer,et al.  Neutralization of divergent HIV-1 isolates by conformation-dependent human antibodies to Gp120. , 1991, Science.

[47]  N. Haigwood,et al.  Effect of intron A from human cytomegalovirus (Towne) immediate-early gene on heterologous expression in mammalian cells. , 1991, Nucleic acids research.

[48]  C. Cheng‐Mayer,et al.  Biologic features of HIV-1 that correlate with virulence in the host. , 1988, Science.

[49]  R. D. Francis,et al.  Some biological and physical properties of molluscum contagiosum virus propagated in cell culture , 1976, Journal of virology.

[50]  S. Zolla-Pazner,et al.  Immune correlates of protection from HIV infection and AIDS. , 1997, Immunology today.

[51]  S. Rowland-Jones,et al.  Role of cellular immunity in protection against HIV infection. , 1997, Advances in immunology.

[52]  A. Sjölander,et al.  Mechanisms behind the immune response induced by immunostimulating complexes. , 1994, AIDS research and human retroviruses.

[53]  J. Heeney,et al.  HIV-1 envelope-elicited neutralizing antibody titres correlate with protection and virus load in chimpanzees. , 1994, Vaccine.

[54]  J. Sodroski,et al.  Infection of cynomolgus monkeys with a chimeric HIV-1/SIVmac virus that expresses the HIV-1 envelope glycoproteins. , 1992, Journal of acquired immune deficiency syndromes.

[55]  A. Osterhaus,et al.  Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses , 1984, Nature.